Versor Investments LP Acquires Shares of 9,500 Encompass Health Co. (NYSE:EHC)

Versor Investments LP bought a new position in shares of Encompass Health Co. (NYSE:EHC - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 9,500 shares of the company's stock, valued at approximately $634,000.

A number of other large investors also recently modified their holdings of the business. International Assets Investment Management LLC acquired a new stake in Encompass Health during the fourth quarter worth about $20,210,000. Jackson Creek Investment Advisors LLC raised its position in shares of Encompass Health by 364.4% during the 4th quarter. Jackson Creek Investment Advisors LLC now owns 13,910 shares of the company's stock worth $928,000 after purchasing an additional 10,915 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Encompass Health by 2.3% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,318,784 shares of the company's stock worth $87,989,000 after purchasing an additional 29,926 shares during the last quarter. Phocas Financial Corp. boosted its position in Encompass Health by 112.4% during the 4th quarter. Phocas Financial Corp. now owns 99,875 shares of the company's stock valued at $6,664,000 after purchasing an additional 52,847 shares during the period. Finally, Nordea Investment Management AB grew its stake in Encompass Health by 21.0% during the 4th quarter. Nordea Investment Management AB now owns 101,705 shares of the company's stock worth $6,787,000 after buying an additional 17,684 shares during the last quarter. 97.25% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Mark J. Tarr sold 44,976 shares of the business's stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the sale, the chief executive officer now directly owns 554,098 shares of the company's stock, valued at $46,139,740.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP John Patrick Darby sold 14,543 shares of the firm's stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $83.94, for a total value of $1,220,739.42. Following the completion of the transaction, the executive vice president now owns 84,773 shares of the company's stock, valued at approximately $7,115,845.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Mark J. Tarr sold 44,976 shares of the business's stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the sale, the chief executive officer now directly owns 554,098 shares in the company, valued at $46,139,740.46. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by insiders.

Encompass Health Price Performance

Shares of EHC stock traded up $0.16 during mid-day trading on Friday, hitting $86.53. 719,298 shares of the stock traded hands, compared to its average volume of 709,185. Encompass Health Co. has a twelve month low of $57.55 and a twelve month high of $86.72. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.37 and a current ratio of 1.37. The company's 50-day simple moving average is $80.24 and its 200-day simple moving average is $72.38. The firm has a market cap of $8.71 billion, a price-to-earnings ratio of 23.39, a price-to-earnings-growth ratio of 1.35 and a beta of 0.92.

Encompass Health (NYSE:EHC - Get Free Report) last released its earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.19. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The firm had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same period in the previous year, the company earned $0.88 earnings per share. Encompass Health's revenue was up 13.4% compared to the same quarter last year. As a group, equities research analysts expect that Encompass Health Co. will post 4.09 earnings per share for the current year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Monday, July 1st will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Friday, June 28th. Encompass Health's dividend payout ratio is presently 16.22%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Truist Financial upped their price target on shares of Encompass Health from $82.00 to $86.00 and gave the stock a "buy" rating in a research report on Friday, February 9th. Royal Bank of Canada reiterated an "outperform" rating and set a $83.00 price objective on shares of Encompass Health in a research report on Friday, February 9th. Stephens restated an "overweight" rating and issued a $85.00 target price on shares of Encompass Health in a research report on Tuesday, January 16th. Mizuho boosted their price target on Encompass Health from $93.00 to $95.00 and gave the stock a "buy" rating in a research report on Thursday, April 25th. Finally, Raymond James reissued a "strong-buy" rating and issued a $95.00 price target (up previously from $85.00) on shares of Encompass Health in a research note on Friday, April 26th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Encompass Health presently has an average rating of "Buy" and a consensus price target of $90.29.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.